{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:24:31Z","timestamp":1794385471679,"version":"4.9.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016302","name":"CEPI","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite large outbreaks in humans seeming improbable for a number of zoonotic pathogens, several pose a concern due to their epidemiological characteristics and evolutionary potential. To enable effective responses to these pathogens in the event that they undergo future emergence, the Coalition for Epidemic Preparedness Innovations is advancing the development of vaccines for several pathogens prioritized by the World Health Organization. A major challenge in this pursuit is anticipating demand for a vaccine stockpile to support outbreak response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a modeling framework for outbreak response for emerging zoonoses under three reactive vaccination strategies to assess sustainable vaccine manufacturing needs, vaccine stockpile requirements, and the potential impact of the outbreak response. This framework incorporates geographically variable zoonotic spillover rates, human-to-human transmission, and the implementation of reactive vaccination campaigns in response to disease outbreaks. As proof of concept, we applied the framework to four priority pathogens: Lassa virus, Nipah virus, MERS coronavirus, and Rift Valley virus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Annual vaccine regimen requirements for a population-wide strategy ranged from &gt; 670,000 (95% prediction interval 0\u20133,630,000) regimens for Lassa virus to 1,190,000 (95% PrI 0\u20138,480,000) regimens for Rift Valley fever virus, while the regimens required for ring vaccination or targeting healthcare workers (HCWs) were several orders of magnitude lower (between 1\/25 and 1\/700) than those required by a population-wide strategy. For each pathogen and vaccination strategy, reactive vaccination typically prevented fewer than 10% of cases, because of their presently low\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>0<\/jats:sub>\n                      values. Targeting HCWs had a higher per-regimen impact than population-wide vaccination.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our framework provides a flexible methodology for estimating vaccine stockpile needs and the geographic distribution of demand under a range of outbreak response scenarios. Uncertainties in our model estimates highlight several knowledge gaps that need to be addressed to target vulnerable populations more accurately. These include surveillance gaps that mask the true geographic distribution of each pathogen, details of key routes of spillover from animal reservoirs to humans, and the role of human-to-human transmission outside of healthcare settings. In addition, our estimates are based on the current epidemiology of each pathogen, but pathogen evolution could alter vaccine stockpile requirements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-022-02405-1","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T20:02:33Z","timestamp":1655323353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Projecting vaccine demand and impact for emerging zoonotic pathogens"],"prefix":"10.1186","volume":"20","author":[{"given":"Anita","family":"Lerch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quirine A.","family":"ten Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00efna","family":"L\u2019Azou Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison A.","family":"Bettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Bernuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina A. V.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan M.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir S.","family":"Siraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebbiena M.","family":"Bron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson S.","family":"Hartlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sojung","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathyrn","family":"Strimbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalene","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Alex","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-6100","authenticated-orcid":false,"given":"Sean M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"issue":"4","key":"2405_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450\u20132.","journal-title":"Nat Med"},{"key":"2405_CR2","volume-title":"WHO Coronavirus (COVID-19) Dashboard","author":"WHO","year":"2020","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard. 2020 [cited 2021 May 1]. Available from: https:\/\/covid19.who.int\/"},{"issue":"6967","key":"2405_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature02104","volume":"426","author":"R Antia","year":"2003","unstructured":"Antia R, Regoes RR, Koella JC, Bergstrom CT. The role of evolution in the emergence of infectious diseases. Nature. 2003;426(6967):658\u201361.","journal-title":"Nature."},{"issue":"5","key":"2405_CR4","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1128\/JVI.02041-07","volume":"82","author":"T Sheahan","year":"2008","unstructured":"Sheahan T, Rockx B, Donaldson E, Sims A, Pickles R, Corti D, et al. Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J Virol. 2008;82(5):2274\u201385.","journal-title":"J Virol"},{"issue":"9857","key":"2405_CR5","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/S0140-6736(12)61684-5","volume":"380","author":"SS Morse","year":"2012","unstructured":"Morse SS, Mazet JAK, Woolhouse M, Parrish CR, Carroll D, Karesh WB, et al. Prediction and prevention of the next pandemic zoonosis. Lancet. 2012;380(9857):1956\u201365.","journal-title":"Lancet."},{"issue":"7","key":"2405_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMp1613577","volume":"376","author":"J-A R\u00f8ttingen","year":"2017","unstructured":"R\u00f8ttingen J-A, Gouglas D, Feinberg M, Plotkin S, Raghavan KV, Witty A, et al. New vaccines against epidemic infectious diseases. N Engl J Med. 2017;376(7):610\u20133.","journal-title":"N Engl J Med"},{"issue":"4","key":"2405_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","volume":"27","author":"J-L Excler","year":"2021","unstructured":"Excler J-L, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. 2021;27(4):591\u2013600.","journal-title":"Nat Med"},{"key":"2405_CR8","volume-title":"Prioritizing diseases for research and development in emergency contexts","author":"WHO","year":"2016","unstructured":"WHO. Prioritizing diseases for research and development in emergency contexts. 2016 [cited 2021 Apr 30]. Available from: https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts"},{"issue":"1","key":"2405_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/epirev\/mxz012","volume":"41","author":"D Gouglas","year":"2019","unstructured":"Gouglas D, Christodoulou M, Plotkin SA, Hatchett R. CEPI: driving progress toward epidemic preparedness and response. Epidemiol Rev. 2019;41(1):28\u201333.","journal-title":"Epidemiol Rev"},{"issue":"1","key":"2405_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00103-019-03061-2","volume":"63","author":"V Bernasconi","year":"2020","unstructured":"Bernasconi V, Kristiansen PA, Whelan M, Rom\u00e1n RG, Bettis A, Yimer SA, et al. Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63(1):65\u201373.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"9","key":"2405_CR11","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.vaccine.2019.12.055","volume":"38","author":"B Huneycutt","year":"2020","unstructured":"Huneycutt B, Lurie N, Rotenberg S, Wilder R, Hatchett R. Finding equipoise: CEPI revises its equitable access policy. Vaccine. 2020;38(9):2144\u20138.","journal-title":"Vaccine."},{"key":"2405_CR12","volume-title":"Priority diseases \u2013 CEPI","author":"CEPI","year":"2018","unstructured":"CEPI. Priority diseases \u2013 CEPI. 2018 [cited 2021 Apr 30]. Available from: https:\/\/cepi.net\/research_dev\/priority-diseases\/"},{"key":"2405_CR13","volume-title":"CEPI-funded Nipah virus vaccine candidate first to reach phase 1 clinical trial \u2013 CEPI","author":"CEPI","year":"2020","unstructured":"CEPI. CEPI-funded Nipah virus vaccine candidate first to reach phase 1 clinical trial \u2013 CEPI. 2020 [cited 2021 Sep 24]. Available from: https:\/\/cepi.net\/news_cepi\/cepi-funded-nipah-virus-vaccine-candidate-first-to-reach-phase-1-clinical-trial\/"},{"key":"2405_CR14","volume-title":"EDCTP and CEPI funding moves IAVI\u2019s Lassa fever vaccine candidate into advanced clinical development \u2013 CEPI","author":"CEPI","year":"2021","unstructured":"CEPI. EDCTP and CEPI funding moves IAVI\u2019s Lassa fever vaccine candidate into advanced clinical development \u2013 CEPI. 2021 [cited 2021 Sep 24]. Available from: https:\/\/cepi.net\/news_cepi\/edctp-and-cepi-funding-moves-iavis-lassa-fever-vaccine-candidate-into-advanced-clinical-development\/"},{"issue":"5948","key":"2405_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1126\/science.1175570","volume":"325","author":"J Medlock","year":"2009","unstructured":"Medlock J, Galvani AP. Optimizing influenza vaccine distribution. Science. 2009;325(5948):1705\u20138.","journal-title":"Science."},{"key":"2405_CR16","doi-asserted-by":"publisher","unstructured":"Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371 916\u2013921. Available from: https:\/\/doi.org\/10.1126\/science.abe6959","DOI":"10.1126\/science.abe6959"},{"key":"2405_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-ento-010715-023819","volume":"61","author":"KJ Linthicum","year":"2016","unstructured":"Linthicum KJ, Britch SC, Anyamba A. Rift Valley fever: an emerging mosquito-borne disease. Annu Rev Entomol. 2016;61:395\u2013415.","journal-title":"Annu Rev Entomol"},{"issue":"32","key":"2405_CR18","doi-asserted-by":"publisher","first-page":"9081","DOI":"10.1073\/pnas.1519235113","volume":"113","author":"S Cauchemez","year":"2016","unstructured":"Cauchemez S, Nouvellet P, Cori A, Jombart T, Garske T, Clapham H, et al. Unraveling the drivers of MERS-CoV transmission. Proc Natl Acad Sci U S A. 2016;113(32):9081\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2405_CR19","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","volume":"379","author":"KJ Siddle","year":"2018","unstructured":"Siddle KJ, Eromon P, Barnes KG, Mehta S, Oguzie JU, Odia I, et al. Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018. N Engl J Med. 2018;379(18):1745\u201353.","journal-title":"N Engl J Med"},{"issue":"19","key":"2405_CR20","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMoa1805376","volume":"380","author":"B Nikolay","year":"2019","unstructured":"Nikolay B, Salje H, Hossain MJ, Khan AKMD, Sazzad HMS, Rahman M, et al. Transmission of Nipah virus - 14 years of investigations in Bangladesh. N Engl J Med. 2019;380(19):1804\u201314.","journal-title":"N Engl J Med"},{"key":"2405_CR21","volume-title":"WHO target product profiles for MERS-CoV vaccines","author":"WHO","year":"2017","unstructured":"WHO. WHO target product profiles for MERS-CoV vaccines. 2017. Available from: https:\/\/www.who.int\/blueprint\/what\/research-development\/MERS_CoV_TPP_15052017.pdf?ua=1"},{"key":"2405_CR22","volume-title":"WHO target product profile for Nipah virus vaccine","author":"WHO","year":"2017","unstructured":"WHO. WHO target product profile for Nipah virus vaccine. 2017. Available from: https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Nipah_virus_vaccineTPP.pdf"},{"key":"2405_CR23","volume-title":"WHO target product profile for Lassa virus vaccine","author":"WHO","year":"2017","unstructured":"WHO. WHO target product profile for Lassa virus vaccine. 2017. Available from: https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/LassaVirusVaccineTPP.PDF?ua=1"},{"key":"2405_CR24","volume-title":"Target product profiles for Rift valley fever virus vaccines","author":"WHO","year":"2019","unstructured":"WHO. Target product profiles for Rift valley fever virus vaccines. 2019. Available from: https:\/\/www.who.int\/docs\/default-source\/blue-print\/call-for-comments\/tpp-rift-valley-fever-vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314_2"},{"issue":"8","key":"2405_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/trstmh\/trv047","volume":"109","author":"AQN Mylne","year":"2015","unstructured":"Mylne AQN, Pigott DM, Longbottom J, Shearer F, Duda KA, Messina JP, et al. Mapping the zoonotic niche of Lassa fever in Africa. Trans R Soc Trop Med Hyg. 2015;109(8):483\u201392.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6381","key":"2405_CR26","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1126\/science.359.6381.1201","volume":"359","author":"L Roberts","year":"2018","unstructured":"Roberts L. Nigeria hit by unprecedented Lassa fever outbreak. Science. 2018;359(6381):1201\u20132.","journal-title":"Science."},{"issue":"3","key":"2405_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3201\/eid0703.017312","volume":"7","author":"JM Yob","year":"2001","unstructured":"Yob JM, Field H, Rashdi AM, Morrissy C, van der Heide B, Rota P, et al. Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia. Emerg Infect Dis. 2001;7(3):439\u201341.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"2405_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3201\/eid1508.081237","volume":"15","author":"SP Luby","year":"2009","unstructured":"Luby SP, Hossain MJ, Gurley ES, Ahmed BN, Banu S, Khan SU, et al. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007. Emerg Infect Dis. 2009;15(8):1229\u201335.","journal-title":"Emerg Infect Dis"},{"issue":"66","key":"2405_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1098\/rsif.2011.0223","volume":"9","author":"JRC Pulliam","year":"2012","unstructured":"Pulliam JRC, Epstein JH, Dushoff J, Rahman SA, Bunning M, Jamaluddin AA, et al. Agricultural intensification, priming for persistence and the emergence of Nipah virus: a lethal bat-borne zoonosis. J R Soc Interface. 2012;9(66):89\u2013101.","journal-title":"J R Soc Interface"},{"key":"#cr-split#-2405_CR30.1","doi-asserted-by":"crossref","unstructured":"Girish Kumar CP, Sugunan AP, Yadav P, Kurup KK, Aarathee R, Manickam P, et al. Infections among contacts of patients with Nipah virus, India. Emerg Infect Dis J. 2019;25","DOI":"10.3201\/eid2505.181352"},{"key":"#cr-split#-2405_CR30.2","unstructured":"(5) Available from: https:\/\/wwwnc.cdc.gov\/eid\/article\/25\/5\/pdfs\/18-1352.pdf. [cited 2020 Dec 29]."},{"key":"2405_CR31","doi-asserted-by":"publisher","unstructured":"Anthony SJ, Gilardi K, Menachery VD, Goldstein T, Ssebide B, Mbabazi R, et al. Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. MBio. 2017 ;8(2). Available from: https:\/\/doi.org\/10.1128\/mBio.00373-17","DOI":"10.1128\/mBio.00373-17"},{"key":"2405_CR32","doi-asserted-by":"publisher","unstructured":"M\u00fcller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15:559\u2013564. Available from: https:\/\/doi.org\/10.1016\/s1473-3099(15)70090-3","DOI":"10.1016\/s1473-3099(15)70090-3"},{"key":"2405_CR33","doi-asserted-by":"publisher","unstructured":"Dudas G, Carvalho LM, Rambaut A, Bedford T. MERS-CoV spillover at the camel-human interface. Elife. 2018;7. Available from: https:\/\/doi.org\/10.7554\/eLife.31257","DOI":"10.7554\/eLife.31257"},{"issue":"8","key":"2405_CR34","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S1473-3099(18)30127-0","volume":"18","author":"DS Hui","year":"2018","unstructured":"Hui DS, Azhar EI, Kim Y-J, Memish ZA, Oh M-D, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18(8):e217\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"7009","key":"2405_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","volume":"311","author":"SP Fisher-Hoch","year":"1995","unstructured":"Fisher-Hoch SP, Tomori O, Nasidi A, Perez-Oronoz GI, Fakile Y, Hutwagner L, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ. 1995;311(7009):857\u20139.","journal-title":"BMJ."},{"issue":"2","key":"2405_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3947\/ic.2016.48.2.99","volume":"48","author":"SH Park","year":"2016","unstructured":"Park SH, Kim Y-S, Jung Y, Choi SY, Cho N-H, Jeong HW, et al. Outbreaks of Middle East respiratory syndrome in two hospitals initiated by a single patient in Daejeon, South Korea. Infect Chemother. 2016;48(2):99\u2013107.","journal-title":"Infect Chemother"},{"issue":"5","key":"2405_CR37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1306742","volume":"369","author":"A Assiri","year":"2013","unstructured":"Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DAT, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"2405_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/vetres\/2010033","volume":"41","author":"M Pepin","year":"2010","unstructured":"Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res. 2010;41(6):61.","journal-title":"Vet Res"},{"issue":"6","key":"2405_CR39","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/pathogens10060708","volume":"10","author":"GM Bron","year":"2021","unstructured":"Bron GM, Strimbu K, Cecilia H, Lerch A, Moore SM, Tran Q, et al. Over 100 years of Rift Valley fever: a patchwork of data on pathogen spread and spillover. Pathogens. 2021;10(6):708.","journal-title":"Pathogens."},{"key":"2405_CR40","doi-asserted-by":"publisher","unstructured":"Gerken KN, LaBeaud AD, Mandi H, L\u2019Azou Jackson M, Breugelmans JG, King CH. Paving the way for human vaccination against Rift Valley fever virus: a systematic literature review of RVFV epidemiology from 1999 to 2021. medRxiv. 2021; Available from: https:\/\/doi.org\/10.1101\/2021.09.29.21264307","DOI":"10.1101\/2021.09.29.21264307"},{"issue":"3","key":"2405_CR41","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1073\/pnas.0806490106","volume":"106","author":"A Anyamba","year":"2009","unstructured":"Anyamba A, Chretien J-P, Small J, Tucker CJ, Formenty PB, Richardson JH, et al. Prediction of a Rift Valley fever outbreak. Proc Natl Acad Sci U S A. 2009;106(3):955\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2_Suppl","key":"2405_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4269\/ajtmh.2010.09-0289","volume":"83","author":"A Anyamba","year":"2010","unstructured":"Anyamba A, Linthicum KJ, Small J, Britch SC, Pak E, de La Rocque S, et al. Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006\u20132008 and possible vector control strategies. Am J Trop Med Hyg. 2010;83(2_Suppl):43\u201351.","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"2405_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004314","volume":"9","author":"NA Al-Hamdan","year":"2015","unstructured":"Al-Hamdan NA, Panackal AA, Al Bassam TH, Alrabea A, Al Hazmi M, Al Mazroa Y, et al. The risk of nosocomial transmission of Rift Valley fever. PLoS Negl Trop Dis. 2015;9(12):e0004314.","journal-title":"PLoS Negl Trop Dis"},{"key":"2405_CR44","unstructured":"CSR. World Health Organization - Eastern Mediterranean Region. [cited 2019 Mar 19]. Available from: http:\/\/www.emro.who.int\/pandemic-epidemic-diseases\/mers-cov\/mers-situation-update-february-2019.html"},{"key":"2405_CR45","volume-title":"ProMED-mail","author":"ProMED-mail","year":"2020","unstructured":"ProMED-mail. ProMED-mail. 2020 [cited 2020 Dec 31]. Available from: https:\/\/promedmail.org\/"},{"key":"2405_CR46","unstructured":"Ministry of Health - Kingdom of Saudi Arabia. 2020 [cited 2020 Dec 31]. Available from: https:\/\/www.moh.gov.sa\/en\/CCC\/events\/national\/Pages\/2020.aspx"},{"key":"2405_CR47","volume-title":"Nigeria Centre for Disease Control","author":"Nigeria Centre for Disease Control","year":"2020","unstructured":"Nigeria Centre for Disease Control. Nigeria Centre for Disease Control. 2020 [cited 2020 Dec 31]. Available from: https:\/\/ncdc.gov.ng\/diseases\/sitreps\/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria"},{"issue":"2","key":"2405_CR48","doi-asserted-by":"publisher","first-page":"378","DOI":"10.32614\/RJ-2017-066","volume":"9","author":"ME Brooks","year":"2017","unstructured":"Brooks ME, Kristensen K, Van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. RJ. 2017;9(2):378\u2013400.","journal-title":"RJ"},{"issue":"1","key":"2405_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41597-019-0142-2","volume":"6","author":"J Maina","year":"2019","unstructured":"Maina J, Ouma PO, Macharia PM, Alegana VA, Mitto B, Fall IS, et al. A spatial database of health facilities managed by the public health sector in sub Saharan Africa. Sci Data. 2019;6(1):134.","journal-title":"Sci Data"},{"key":"2405_CR50","doi-asserted-by":"publisher","unstructured":"Saameli R, Kalubi D, Herringer M, Sutton T, de Roodenbeke E. Healthsites.io: The Global Healthsites Mapping Project. Technol Dev. 2018. p. 53\u201359. Available from: https:\/\/doi.org\/10.1007\/978-3-319-91068-0_5","DOI":"10.1007\/978-3-319-91068-0_5"},{"key":"#cr-split#-2405_CR51.1","doi-asserted-by":"crossref","unstructured":"Lo Iacono G, Cunningham AA, Fichet-Calvet E, Garry RF, Grant DS, Khan SH, et al. Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: the case of Lassa fever. PLoS Negl Trop Dis. 2015;9","DOI":"10.1371\/journal.pntd.0003398"},{"key":"#cr-split#-2405_CR51.2","unstructured":"(1) Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25569707\/. [cited 2020 Dec 29]."},{"issue":"2","key":"2405_CR52","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/biostatistics\/4.2.279","volume":"4","author":"CP Farrington","year":"2003","unstructured":"Farrington CP, Kanaan MN, Gay NJ. Branching process models for surveillance of infectious diseases controlled by mass vaccination. Biostatistics. 2003;4(2):279\u201395.","journal-title":"Biostatistics."},{"issue":"1","key":"2405_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S1473-3099(13)70304-9","volume":"14","author":"S Cauchemez","year":"2014","unstructured":"Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A, et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis. 2014;14(1):50\u20136.","journal-title":"Lancet Infect Dis"},{"issue":"9893","key":"2405_CR54","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0140-6736(13)61492-0","volume":"382","author":"R Breban","year":"2013","unstructured":"Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet. 2013;382(9893):694\u20139.","journal-title":"Lancet."},{"key":"2405_CR55","doi-asserted-by":"publisher","unstructured":"Poletto C, Pelat C, Levy-Bruhl D, Yazdanpanah Y, Boelle PY, Colizza V. Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in the Middle East and risk of international spread using a novel maximum likelihood analysis approach. Euro Surveill. 2014 ;19(23). Available from: https:\/\/doi.org\/10.2807\/1560-7917.es2014.19.23.20824","DOI":"10.2807\/1560-7917.es2014.19.23.20824"},{"key":"2405_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.epidem.2014.09.011","volume":"9","author":"G Chowell","year":"2014","unstructured":"Chowell G, Blumberg S, Simonsen L, Miller MA, Viboud C. Synthesizing data and models for the spread of MERS-CoV, 2013: key role of index cases and hospital transmission. Epidemics. 2014;9:40\u201351.","journal-title":"Epidemics."},{"issue":"25","key":"2405_CR57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2807\/1560-7917.ES2015.20.25.21167","volume":"20","author":"AJ Kucharski","year":"2015","unstructured":"Kucharski AJ, Althaus CL. The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission. Euro Surveill. 2015;20(25):14\u20138.","journal-title":"Euro Surveill"},{"issue":"19","key":"2405_CR58","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMoa1805376","volume":"380","author":"B Nikolay","year":"2019","unstructured":"Nikolay B. Transmission of Nipah virus - 14 years of investigations in Bangladesh. N Engl J Med. 2019;380(19):1804\u201314.","journal-title":"N Engl J Med"},{"issue":"7","key":"2405_CR59","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2460\/javma.234.7.883","volume":"234","author":"BH Bird","year":"2009","unstructured":"Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ. Rift Valley fever virus. J Am Vet Med Assoc. 2009;234(7):883\u201393.","journal-title":"J Am Vet Med Assoc"},{"issue":"9","key":"2405_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002120","volume":"13","author":"M Ali","year":"2016","unstructured":"Ali M, Debes AK, Luquero FJ, Kim DR, Park JY, Digilio L, et al. Potential for controlling cholera using a ring vaccination strategy: re-analysis of data from a cluster-randomized clinical trial. PLoS Med. 2016;13(9):e1002120.","journal-title":"PLoS Med"},{"key":"2405_CR61","doi-asserted-by":"publisher","unstructured":"Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, John Edmunds W, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet. 2017;389:505\u2013518. Available from: https:\/\/doi.org\/10.1016\/s0140-6736(16)32621-6","DOI":"10.1016\/s0140-6736(16)32621-6"},{"issue":"4","key":"2405_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.4","volume":"31","author":"AJ Tatem","year":"2017","unstructured":"Tatem AJ. WorldPop, open data for spatial demography. Sci Data. 2017;31(4):170004.","journal-title":"Sci Data"},{"key":"2405_CR63","volume-title":"The Global Health Observatory","author":"WHO","year":"2021","unstructured":"WHO. The Global Health Observatory. 2021 [cited 2021 Mar 12]. Available from: https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/indicator-groups\/indicator-group-details\/GHO\/sdg-target-3.c-health-workforce"},{"issue":"3","key":"2405_CR64","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S1473-3099(14)70999-5","volume":"15","author":"C Yen","year":"2015","unstructured":"Yen C, Hyde TB, Costa AJ, Fernandez K, Tam JS, Hugonnet S, et al. The development of global vaccine stockpiles. Lancet Infect Dis. 2015;15(3):340\u20137.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2405_CR65","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4269\/ajtmh.1994.50.663","volume":"50","author":"ML Wilson","year":"1994","unstructured":"Wilson ML, Chapman LE, Hall DB, Dykstra EA, Ba K, Zeller HG, et al. Rift Valley fever in rural northern Senegal: human risk factors and potential vectors. Am J Trop Med Hyg. 1994;50(6):663\u201375.","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"2405_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006412","volume":"12","author":"L Nyakarahuka","year":"2018","unstructured":"Nyakarahuka L, de St MA, Purpura L, Ervin E, Balinandi S, Tumusiime A, et al. Prevalence and risk factors of Rift Valley fever in humans and animals from Kabale district in Southwestern Uganda, 2016. PLoS Negl Trop Dis. 2018;12(5):e0006412.","journal-title":"PLoS Negl Trop Dis"},{"key":"2405_CR67","doi-asserted-by":"publisher","unstructured":"Msimang V, Thompson PN, Jansen van Vuren P, Tempia S, Cordel C, Kgaladi J, et al. Rift Valley fever virus exposure amongst farmers, farm workers, and veterinary professionals in Central South Africa. Viruses. 2019 ;11(2). Available from: https:\/\/doi.org\/10.3390\/v11020140","DOI":"10.3390\/v11020140"},{"key":"2405_CR68","doi-asserted-by":"publisher","unstructured":"Chika-Igwenyi Nneka M, Harrison Rebecca E, Psarra Christina, Gil-Cuesta Julita, Gulamhusein Maria, Onwe Emeka O, et al. Early onset of neurological features differentiates two outbreaks of Lassa fever in Ebonyi state, Nigeria during 2017\u20132018. PLoS Negl Trop Dis. 2021;15(3):e0009169. https:\/\/doi.org\/10.1371\/journal.pntd.0009169.","DOI":"10.1371\/journal.pntd.0009169"},{"issue":"1","key":"2405_CR69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/vbz.2011.0656","volume":"12","author":"MA Rahman","year":"2012","unstructured":"Rahman MA, Hossain MJ, Sultana S, Homaira N, Khan SU, Rahman M, et al. Date palm sap linked to Nipah virus outbreak in Bangladesh, 2008. Vector Borne Zoonotic Dis. 2012;12(1):65\u201372.","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"4","key":"2405_CR70","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3201\/eid2204.151747","volume":"22","author":"MS Islam","year":"2016","unstructured":"Islam MS, Sazzad HMS, Satter SM, Sultana S, Hossain MJ, Hasan M, et al. Nipah virus transmission from bats to humans associated with drinking traditional liquor made from date palm sap, Bangladesh, 2011-2014. Emerg Infect Dis. 2016;22(4):664\u201370.","journal-title":"Emerg Infect Dis"},{"key":"2405_CR71","doi-asserted-by":"publisher","unstructured":"Grais RF, Conlan AJK, Ferrari MJ, Djibo A, Le Menach A, Bj\u00f8rnstad ON, et al. Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger. J R Soc Interface. 2008;5(18):67\u201374. https:\/\/doi.org\/10.1098\/rsif.2007.1038.","DOI":"10.1098\/rsif.2007.1038"},{"issue":"1798","key":"2405_CR72","doi-asserted-by":"publisher","first-page":"20141341","DOI":"10.1098\/rspb.2014.1341","volume":"282","author":"Andrew S Azman","year":"2015","unstructured":"Azman Andrew S, Lessler Justin. Reactive vaccination in the presence of disease hotspots. Proc R Soc B Biol Sci. 2015;282(1798):20141341. https:\/\/doi.org\/10.1098\/rspb.2014.1341.","journal-title":"Proc R Soc B Biol Sci"},{"issue":"20","key":"2405_CR73","doi-asserted-by":"publisher","first-page":"10178","DOI":"10.1073\/pnas.1817329116","volume":"116","author":"Chad R Wells","year":"2019","unstructured":"Wells Chad R, Pandey Abhishek, Parpia Alyssa S, Fitzpatrick Meagan C, Meyers Lauren A, Singer Burton H, Galvani Alison P. Ebola vaccination in the Democratic Republic of the Congo. Proc Natl Acad Sci. 2019;116(20):10178\u201383. https:\/\/doi.org\/10.1073\/pnas.1817329116.","journal-title":"Proc Natl Acad Sci"},{"key":"2405_CR74","doi-asserted-by":"publisher","unstructured":"Grange ZL, Goldstein T, Johnson CK, Anthony S, Gilardi K, Daszak P, et al. Ranking the risk of animal-to-human spillover for newly discovered viruses. Proc Natl Acad Sci U S A. 2021 ;118(15). Available from: https:\/\/doi.org\/10.1073\/pnas.2002324118","DOI":"10.1073\/pnas.2002324118"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02405-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02405-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02405-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T20:02:53Z","timestamp":1655323373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02405-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2405"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02405-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.09.21266135","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"12 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}